The nation of Zimbabwe has rejected a substantial American healthcare agreement worth $367m (£272m) spanning five years over Washington's demand for sensitive information.
The decision came to light after a government memo from December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesperson has since clarified that the US was demanding access to health data for scientific study and profit while was unwilling to guarantee the benefits from any future vaccines.
"We must now begin the difficult and regrettable task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for further talks to reach a agreement agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Wider Implications
Zimbabwe's decision follows a similar situation in Kenya, where a court halted a similar deal with the US after concerns were filed about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government agreements to boost transparency and accountability.
According to statements, 16 nations in Africa have to date agreed to similar health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, with no corresponding assurance of benefiting from any medical innovations – like new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our country would supply the raw materials for scientific discovery without any certainty that the end products would be available to our population if a new health crisis emerge."
National Interest and Global Health
He also said that the American exit from the global health body and its pursuit of one-on-one deals were upending frameworks previously established through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This system is intended to guarantee that when a nation contributes its data, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," he added.
"We are open to continued dialogue with our US partners on how future collaboration might be structured in a way that honours the sovereignty and interests of both nations."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but urged that talks should continue since much of the country's Aids initiatives were funded by foreign aid.
"Where technical issues arise, such as those involving information security or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," the group added.
The halted deal emphasises the ongoing challenges between accepting crucial international aid and safeguarding national sovereignty in an ever more data-driven world.